Addex Therapeutics (FRA:APE) Total Operating Expense: €2.92 Mil (TTM As of Mar. 2026)


What is Addex Therapeutics Total Operating Expense?

Addex Therapeutics FRA:APE +1.20% Total Operating Expense is €2.92 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Addex Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was €0.53 Mil. Addex Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €2.92 Mil.

Addex Therapeutics Total Operating Expense Related Terms

Addex Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Total Operating Expense Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.70 12.12 4.09 3.38 3.05

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.78 0.78 0.84 0.53

Addex Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €2.92 Mil mean?
Addex Therapeutics (FRA:APE) has a Total Operating Expense of €2.92 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Addex Therapeutics and its competitors.
Is Addex Therapeutics' Total Operating Expense too high?
Addex Therapeutics' current Total Operating Expense is €2.92 Mil.
How does Addex Therapeutics' Total Operating Expense compare to VRTX and REGN?
Addex Therapeutics' Total Operating Expense of €2.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current Total Operating Expense is €2.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Addex Therapeutics (FRA:APE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.04 — trading 320% above its estimated fair value. The current Total Operating Expense is €2.92 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current Total Operating Expense is €2.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.